Valuation : Rezolute, Inc.

Market Cap 483M 416M 390M 356M 671M 46.13B 673M 4.63B 1.81B 23.28B 1.81B 1.77B 77.21B P/E 2026 *
-6.6x
P/E 2027 * -7.11x
Enterprise Value 483M 416M 390M 356M 671M 46.13B 673M 4.63B 1.81B 23.28B 1.81B 1.77B 77.21B EV / Sales 2026 *
-
EV / Sales 2027 * 209x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Rezolute, Inc.

1 day-7.23%
1 week-9.23%
Current month-2.12%
1 month-5.33%
3 months+40.00%
6 months+47.13%
Current year+95.76%
1 week 4.58
Extreme 4.58
5.22
1 month 4.44
Extreme 4.44
5.64
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 29/01/2013
Director of Finance/CFO 52 22/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 03/05/2022
Director/Board Member 55 19/11/2019
Chairman 68 09/02/2019
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Tax

Chief Technology Officer

-3,062 0.0035%
02/07/26 Tax

Chief Financial Officer

-3,062 0.0035%
02/07/26 Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-7.23%-9.23%-35.11%+239.71% 483M
-1.59%-3.35%+52.37%+91.62% 69.54B
-2.30%+1.23%+44.40%+88.21% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-1.67%+0.24%+29.05%-19.81% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.32%-2.66%+44.65%+194.98% 28.24B
Weighted average by Cap. -1.81%-1.52%+50.04%+149.28%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.86M 1.7M 3.2M 220M 3.21M 22.09M 8.62M 111M 8.65M 8.46M 369M
Net income -72.7M -62.64M -58.73M -53.62M -101M -6.95B -101M -697M -272M -3.51B -273M -267M -11.63B -75.12M -64.73M -60.69M -55.4M -104M -7.18B -105M -720M -281M -3.62B -282M -276M -12.02B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
28/08/26 US$4.620 -7.23% 1,084,885
27/08/26 US$4.980 -1.19% 784,234
26/08/26 US$5.040 +0.60% 1,368,016
25/08/26 US$5.010 0.00% 1,798,771
24/08/26 US$5.010 -1.57% 1,297,415
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.620USD
Average target price
7.667USD
Spread / Average Target
+65.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock